Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
Wednesday, December 8, 2010 - 09:30
in Health & Medicine
Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major...